首页> 美国卫生研究院文献>IUCrJ >Neutron structure of human carbonic anhydrase II in complex with methazolamide: mapping the solvent and hydrogen-bonding patterns of an effective clinical drug
【2h】

Neutron structure of human carbonic anhydrase II in complex with methazolamide: mapping the solvent and hydrogen-bonding patterns of an effective clinical drug

机译:人碳酸酐酶II与甲唑酰胺复合的中子结构:绘制有效临床药物的溶剂和氢键模式

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Carbonic anhydrases (CAs; EC 4.2.1.1) catalyze the interconversion of CO2 and HCO3 , and their inhibitors have long been used as diuretics and as a therapeutic treatment for many disorders such as glaucoma and epilepsy. Acetazolamide (AZM) and methazolamide (MZM, a methyl derivative of AZM) are two of the classical CA inhibitory drugs that have been used clinically for decades. The jointly refined X-rayeutron structure of MZM in complex with human CA isoform II (hCA II) has been determined to a resolution of 2.2 Å with an R cryst of ∼16.0%. Presented in this article, along with only the second neutron structure of a clinical drug-bound hCA, is an in-depth structural comparison and analyses of differences in hydrogen-bonding network, water-molecule orientation and solvent displacement that take place upon the binding of AZM and MZM in the active site of hCA II. Even though MZM is slightly more hydrophobic and displaces more waters than AZM, the overall binding affinity (K i) for both of the drugs against hCA II is similar (∼10 nM). The plausible reasons behind this finding have also been discussed using molecular dynamics and X-ray crystal structures of hCA II–MZM determined at cryotemperature and room temperature. This study not only allows a direct comparison of the hydrogen bonding, protonation states and solvent orientation/displacement of AZM and MZM, but also shows the significant effect that the methyl derivative has on the solvent organization in the hCA II active site.
机译:碳酸酐酶(CAs; EC 4.2.1.1)催化CO2和HCO3 -的相互转化,长期以来,它们的抑制剂一直被用作利尿剂和多种治疗方法,例如青光眼和癫痫病。乙酰唑胺(AZM)和甲唑胺(MZM,AZM的甲基衍生物)是临床上已使用数十年的两种经典的CA抑制药物。与人CA同工型II(hCA II)配合使用的MZM的联合精制X射线/中子结构已确定为分辨率为2.2Å,R cryst为〜16.0%。本文介绍的只是临床药物结合的hCA的第二种中子结构,是对结构进行深入的结构比较和分析,分析了氢键网络,水分子取向和结合后发生的溶剂置换的差异hCA II活性位点中AZM和MZM的表达。尽管MZM的疏水性略强于AZM,并且置换了更多的水,但两种药物对hCA II的总结合亲和力(K i)相似(〜10 ^ nM)。还使用在低温和室温下测定的hCA II–MZM的分子动力学和X射线晶体结构讨论了这一发现背后的合理原因。这项研究不仅可以直接比较AZM和MZM的氢键,质子化状态和溶剂取向/位移,而且还显示了甲基衍生物对hCA II活性位点中溶剂组织的重要影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号